Beckman Coulter Life Sciences releases assay to quantify antibody aggregation

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has launched its new Valita Aggregation Pure assay. The plate-based 96-well screening tool offers rapid, high-throughput protein aggregation detection and quantification, providing robust aggregation data in as little as 15 minutes.

Traditional workflows in monoclonal antibody production require long wait times of up to six hours to determine protein aggregation levels. The new Valita Aggregation Pure assay delivers a rapid solution, and is compatible with high-performance microplate readers with fluorescence polarization functionality.

The new assay enhances the process development workflow by enabling detection and quantification of antibody aggregation at any stage of time. In less than 15 minutes, aggregation can be quantified by simply adding purified samples to the plate, incubating at room temperature, and measuring aggregation using a plate reader.

Available as 96-well plates and validated with samples concentrated between 200 to 2,000 milligrams per litre, with a detection limit of 0.5% aggregation at 1,000 milligrams per litre, it enables rapid, high-throughput protein aggregation analysis.

"Processing thousands of samples to generate a commercially viable cell line is a complex and tedious process that can slow laboratory workflows. We continue to hear the critical need to rapidly measure antibody aggregation faster than traditional DLS/SLS and HPLC-SEC methods. Our innovation slashes manual steps, the need for additional reagents, and added expense – all in a fraction of the time. We’re confident this will allow laboratory staff to get results faster and focus their efforts on critical research goals," said Dr. Elisa Nent, Global Product Manager - Cell Health.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>